SRC and breast carcinoma: Of the several siRNAs targeting Src that were designed and tested, the most effective one was used to knock down Src in the highly metastatic human breast cancer cell line MDA-MB-435S [17], a cell line in which Src activity is elevated [3] and potentially playing an important role in maintaining its neoplastic phenotype.